Novartis (NYSE:NVS) Shares Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Novartis stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Novartis Price Performance

NVS opened at $130.44 on Thursday. The business has a fifty day moving average of $128.00 and a 200 day moving average of $122.30. The stock has a market cap of $275.54 billion, a P/E ratio of 17.82, a PEG ratio of 1.93 and a beta of 0.60. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 0.50. Novartis AG has a 52-week low of $96.06 and a 52-week high of $134.00.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing analysts’ consensus estimates of $2.26 by ($0.01). The business had revenue of $14.36 billion during the quarter, compared to analysts’ expectations of $13.70 billion. Novartis had a return on equity of 41.21% and a net margin of 26.49%.The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.06 EPS. As a group, sell-side analysts anticipate that Novartis AG will post 8.45 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on NVS shares. Cfra Research upgraded shares of Novartis to a “hold” rating in a research note on Wednesday, October 29th. Wall Street Zen downgraded Novartis from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 1st. Cowen reiterated a “hold” rating on shares of Novartis in a report on Monday, November 10th. Cfra set a $126.00 price target on Novartis and gave the company a “hold” rating in a research note on Wednesday, October 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $122.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NVS. WPG Advisers LLC bought a new stake in Novartis during the first quarter valued at about $25,000. GFG Capital LLC bought a new position in Novartis in the second quarter worth about $26,000. Legacy Investment Solutions LLC purchased a new stake in shares of Novartis during the second quarter valued at about $30,000. Barrett & Company Inc. bought a new stake in shares of Novartis in the 2nd quarter valued at about $31,000. Finally, Valley Wealth Managers Inc. purchased a new position in shares of Novartis in the 3rd quarter worth approximately $31,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.